Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024)
Harmony Biosciences Holdings' (HRMY) quarterly Raw Materials came in at $944000.0 in Q4 2024, down 10.94% year-on-year from $1.1 million in Q1 2024, and down 8.62% quarter-over-quarter from $1.0 million in Q3 2024.
Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024) Analysis & Trends
Harmony Biosciences Holdings has disclosed Raw Materials across 2 years of filings, most recently posting $944000.0 for Q4 2024.
- Raw Materials for Q4 2024 came in at $944000.0, down 10.94% year-over-year; the trailing twelve-month figure through Dec 2024 was $944000.0 (down 10.94% YoY), and the FY2024 annual result was $944000.0, down 10.94% from the prior year.
- Raw Materials came in at $944000.0 for Q4 2024 at Harmony Biosciences Holdings, down from $1.0 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.1 million in Q2 2024 to a low of $944000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Harmony Biosciences Holdings | 1.92 Bn | 1.28 Bn | 170.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 944,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 1.06 Mn |